SO WHAT: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serv ...

NEW YORK, June 13, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 5, 2024. The Rosen Law Firm is investigating the Allegations that Marinus Pharmaceuticals, Inc. ...

The class action concerns whether Marinus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 5, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Marinus securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] NEW YORK, June 13, 2024 (GLOB ...

LOS ANGELES, June 12, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, L ...

LOS ANGELES, June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class ...

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024. Marinus describes itself as a "commercial-stage company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the u ...

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class ...

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period") ...

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under ...

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Did you purchase your shares between March 17, 2021 and May 7, 2024, inclusive? Do you want to discuss your rights? If you purchased or acquired Marinus securities, and/or would like to discuss your legal rights and options please visit Marinus Pharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. According to the Complaint, Defendants failed to ...